Integrin Inhibitor

BTT-3033 (Standard) is the analytical standard of BTT-3033 (HY-110112). This product is intended for research and analytical applications. BTT-3033 is an orally active conformation-selective inhibitor of α2β1 (EC₅₀: 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen I and cell proliferation, and induces cell apoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease.

Anti-Mouse CD41 Antibody (S-R690) reacts with mouse CD41. CD41 is a crucial protein involved in platelet aggregation and hemostasis. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).

Fuzapladib (IS-741) potassium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib potassium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib potassium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.

RUC-1 (Compound 1) is an inhibitor for αIIbβ3 integrin. RUC-1 inhibits fibrin deposition and platelet aggregation in hybrid hαIIb/mβ3 receptors expressing mice. RUC-1 exhibits antithrombotic effect in hαIIb/mβ3 receptor expressing mice.

BMS-688521 (Standard) is the analytical standard of BMS-688521 (HY-10596). This product is intended for research and analytical applications. BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC₅₀ of 2.5 nM in the adhesion assay and an IC₅₀ of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model.

Cilengitide hydrochloride (EMD 121974 hydrochloride) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC₅₀ values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide hydrochloride inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide hydrochloride inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide hydrochloride can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.

EMD527040 (Standard) is the analytical standard of EMD527040 (HY-101473). This product is intended for research and analytical applications. EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research.

Cyclo(RGDyK) (trifluoroacetate) (Standard) is the analytical standard of Cyclo(RGDyK) (trifluoroacetate) (HY-100563). This product is intended for research and analytical applications. Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.

Ro 44-3888 is an orally active and selective GP IIb-IIIa (fibrinogen receptor, integrin α_IIbβ₃) inhibitor with an IC₅₀ of 1.9 nM against the human target. Ro 44-3888 blocks the binding of fibrinogen to GP IIb-IIIa and inhibits human ADP-induced platelet aggregation. Ro 44‑3888 is formed via the metabolism of the double prodrug Ro 48‑3657 (HY-10309). Ro 44-3888 is used in studies related to arterial thrombosis.

Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394).